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that in vitro acidosis inhibits chloride reabsorption in
TALHs.2 The decrease in chloride reabsorption in the
TALHs causes sodium loss and hypercalciuria seen in dRTA.
Another recent paper in Kidney International3 reported
that responses to furosemide are blunted in dRTA patients,
suggesting that sodium reabsorption in the TALHs is
impaired in dRTA.
Even in the same range of urine pH, the urinary
ammonium concentration of dRTA patients is much lower
than in other types of acidosis,4 and the low interstitial pH
can also explain the low NH4
þ excretion rate. NH4
þ
reabsorption in the TALHs is suppressed by the mechanisms
described above, and the low pH in the interstitial space
results in a low NH3/NH4
þ ratio and further decreases the
concentration of NH3, which diffuses into the urinary space
and is trapped as NH4
þ .
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To the Editor: We read with interest the CARTER trial,1 but
we would like to see a number of issues clarified. First, does
the statement that an investigator monitored randomization
in order of the entry of the subjects in each institute mean
that allocation to randomized treatment depended on the
order of presentation of patients? Systematic rather than
random allocation might explain why the cilnidipine
compared with the amlodipine group included 19 more
patients (11.9%). Second, it is remarkable that the authors
did not give more information on the quality control of the
primary outcome measure, the urinary protein-to-creatinine
ratio (UPCR). This multicenter trial ran over 4 years. Were
the measurements done in a central laboratory? Was there
any time trend in the deviation from the UPCR standard in
the quality control program? Was the first, the second, or the
average of both UPCR measurements at entry used as the
baseline? Were single UPCR measurements sufficiently
accurate at each follow-up point, if two were required to
ascertain eligibility? What was the interassay (at baseline) and
intraassay reproducibility of the UPCR measurements? A
variability of 10% would approximate to the observed
differences. Third, although UPCR was not normally
distributed, it was statistically analyzed assuming normality.
Did the results remain consistent after transformation to
approach a normal distribution? Finally, the most important
issue, not reported in the paper, is whether the observed
changes in UPCR were due to the nominator (protein), the
denominator (creatinine), or both?
1. Fujita T, Ando K, Nishimura H et al. Antiproteinuric effect of the calcium
channel blocker cilnidipine added to renin–angiotensin inhibition in
hypertensive patients with chronic renal disease. Kidney Int 2007; 72:
1543–1549.
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We are grateful for the opportunity to respond to the
comments of Dr Staessen.1 First, as mentioned in the
interventions section of the methods in our manuscript,2
randomization was done in order of the entry of the
subjects in each institute. Because only one investigator in
some institutes participated in this study, the allocation
was done at random in order that a number of the two
group subjects equal out for every 10 subjects in each
institute. Thus, even in the institute where more than 10
subjects participated, the number of subjects was often
uneven. Second, this trial was an independent study of
disinterested physicians and done as part of routine care,
and the individual payment was done by individual
patients. Thus, the measurement was not done in a central
laboratory and the quality control of primary outcome
measure was not done. We used the average of two
consecutive measured values of urinary protein-to-creati-
nine ratio (UPCR) during a 4-week observation period
before the treatment, but measured UPCR once at each
follow-up period. Despite this limitation, percentage of
changes of UPCR were consecutively (three times) lower
since early period (3 months) of the treatment in
cilnidipine group as compared with amlodipine group.
Thus, it is suggested that the add-on therapy of cilnidipine
can suppress urinary protein to a greater extent than that
of amlodipine. Third, we reanalyzed data of UPCR as
common logarithm. As a result, baseline value was not
different between cilnidipine and amlodipine groups
(mean±s.d.: 3.10±0.39 vs 3.10±0.34, NS), but logarithm
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of UPCR was lower in cilnidipine group 12 months
after the treatment (2.83±0.68 vs 2.99±0.61, Po0.05,
unpaired t-test). Finally, we measured UPCR in spot urine
but not in the 24 h-collected urine. Urinary protein and
creatinine in spot urine are variable, and then we used
UPCR, which is reported to be correlated to the 24-h
urinary protein excretion.3,4 Both absolute value (after 12
months of the treatment) and percentage of change (after
3–12 months of the treatment) were significantly lower in
cilnidipine group than in amlodipine group.2 Therefore,
the results of CARTER Study suggest that the add-on
therapy of a dual L-/N-type CCB (calcium channel
blocker), cilnidipine, is more effective to reduce urinary
proteinuria than that of L-type CCB, amlodipine, in
proteinuric and hypertensive patients treated with renin–
angiotensin blockades.
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